Skip to content
Sexual & urogenital health

Vaginal estrogen for recurrent UTIs after menopause: what the evidence shows

How vaginal estrogen may help prevent repeat urinary tract infections after menopause, what trials and guidelines say, and when UTI symptoms need care.

  • Urinary health
  • Vaginal estrogen
Written by WarriorBabe Health Editorial TeamPublished · Updated · 7 min read
A woman with glasses laughing in her kitchen
In this article

If you have had one urinary tract infection after another since menopause, you have probably been on more than one round of antibiotics. There is a non-antibiotic option with solid research behind it: low-dose vaginal estrogen [1, 4]. Here is why UTIs become more common after menopause, what the trials found, what guidelines say, and when urinary symptoms need a clinician right away.

Why UTIs can become more common after menopause

Women get UTIs more often than men because the urethra is shorter and closer to the anus, and MedlinePlus lists menopause as another factor that raises the risk [9]. The Menopause Society includes repeat urinary tract infections, along with urgency and burning on urination, among the symptoms of genitourinary syndrome of menopause (GSM), the changes that come from low estrogen [4, 11].

Part of the reason is the vaginal environment. Estrogen supports a population of healthy bacteria called lactobacilli and keeps vaginal pH low, which helps hold back the bacteria that cause infections [5]. After menopause, that balance shifts. A 2025 clinical update in ACOG's journal, *Obstetrics & Gynecology*, describes postmenopausal changes in the urinary and vaginal microbiome that increase vulnerability to recurrent infections, and highlights the role of estrogen therapy [6]. In one classic trial, lactobacilli were absent from every participant's vaginal culture before treatment [2].

Researchers usually define recurrent UTI as three infections in the past 12 months, or two in the past six months [1].

What the research shows

The first placebo-controlled trial

In a 1993 trial, 93 postmenopausal women with recurrent UTIs used either a vaginal estriol cream or a placebo cream and were followed for eight months [2]. The estriol group had 0.5 infections per person per year, compared with 5.9 in the placebo group [2]. Lactobacilli returned after one month in 61% of the women using estriol and in none on placebo, and average vaginal pH fell from 5.5 to 3.8 [2]. Side effects were minor but led 28% of the estriol group and 17% of the placebo group to stop [2].

One caveat: that trial used estriol, a different form of estrogen from the estradiol in US low-dose vaginal products [2, 4].

An estradiol ring trial

A 1999 trial randomized 108 postmenopausal women with recurrent, lab-confirmed UTIs to an estradiol-releasing vaginal ring or no estrogen for 36 weeks [3]. More women stayed infection-free with the ring, and the time to the next infection was longer [3]. This trial was open-label, meaning women knew which group they were in, and the comparison group had no treatment rather than a placebo [3].

Women still free of UTI after 36 weeks in the estradiol ring trial
Estradiol vaginal ring
  • Infection-free ~45%
  • Had a UTI ~55%
No estrogen
  • Infection-free ~20%
  • Had a UTI ~80%

Approximate cumulative share of women remaining free of UTI after 36 weeks, as estimated by the researchers [3].

What reviews of the trials say

A Cochrane review pooled nine randomized trials with 3,345 women [1]. Estrogen taken by mouth did not reduce UTIs compared with placebo in four trials with 2,798 women [1]. Vaginal estrogen reduced the number of women with UTIs compared with placebo in two smaller trials, though results varied with the type of estrogen and how long it was used [1]. Head-to-head with antibiotics, results were mixed: vaginal cream did better than antibiotics in one study, and antibiotics did better than vaginal pessaries in another [1].

Newer reviews point the same way. A 2026 meta-analysis of 17 studies with 2,111 women found lower odds of recurrent UTIs after vaginal estrogen treatment than before it, though those were before-and-after comparisons rather than placebo-controlled results [7]. A 2026 systematic review of non-antibiotic options concluded that vaginal estrogen was effective for postmenopausal women and counted it among the first-line non-antibiotic choices [8].

Key studies of estrogen for recurrent UTIs after menopause
StudyWho was in itWhat was comparedWhat it found
Raz and Stamm, 1993 [2]93 postmenopausal women with recurrent UTIsVaginal estriol cream vs placebo, 8 months0.5 vs 5.9 UTIs per person per year
Eriksen, 1999 [3]108 postmenopausal women with recurrent UTIsEstradiol vaginal ring vs no estrogen, 36 weeksAbout 45% vs 20% stayed infection-free
Cochrane review, 2008 [1]9 trials, 3,345 womenOral or vaginal estrogen vs placebo or other treatmentPills did not reduce UTIs; vaginal estrogen did in two small trials
Meta-analysis, 2026 [7]17 studies, 2,111 womenBefore vs after vaginal estrogenLower odds of recurrent UTI after treatment

What guidelines say

The Menopause Society's 2022 position statement notes that randomized trials have shown a reduced risk of recurrent UTIs with vaginal, but not oral, estrogen [4]. It says low-dose vaginal estrogen may help with urinary symptoms, including preventing recurrent UTIs [4]. It also points out that hormone therapy does not have FDA approval for any urinary health indication [4].

A 2026 review of the guidelines reports that the American Urological Association's guideline (AUA/CUA/SUFU) says clinicians should recommend vaginal estrogen therapy to peri- and postmenopausal women with recurrent UTIs, as a moderate recommendation backed by grade B evidence [5]. The same review notes that UTI prevention is not among the FDA-approved uses listed for vaginal estrogen products [5].

The 2025 update in ACOG's journal says prevention now emphasizes vaginal estrogen, methenamine salts, and other non-antibiotic approaches rather than relying only on preventive antibiotics [6]. MedlinePlus, from the National Library of Medicine, likewise notes that after menopause, estrogen cream used in the vagina may reduce infections [9, 10].

What vaginal estrogen does not do

  • It is for prevention. The trials tested whether vaginal estrogen lowers the number of future infections [1, 2, 3]. An infection you have now still needs testing and treatment [9].
  • Pills are not the same. In the Cochrane review, estrogen taken by mouth did not reduce UTIs [1].
  • It is not FDA-approved for UTIs. Using it for urinary symptoms is a judgment your clinician makes with you [4, 5].
  • It has side effects. In the trials reviewed by Cochrane, these included breast tenderness, vaginal bleeding or spotting, discharge, and vaginal irritation, burning, or itching [1].
  • It is not a decision to make alone after breast cancer. Low-dose vaginal estrogen should be prescribed in consultation with your oncologist [4], and the 2026 review advises caution for women with a history of hormone-sensitive cancer [5].

When UTI symptoms need a clinician

MedlinePlus advises contacting a health care provider for any UTI symptoms [9]. Bladder infection symptoms can include [9]:

  • Cloudy or bloody urine
  • Pain or burning when you urinate
  • Pressure or cramping in the pelvis or lower back
  • A frequent, urgent need to urinate

Get care right away if you also have back or side pain, chills, fever, or vomiting, which can be signs the infection has reached the kidneys [9]. MedlinePlus also notes that in older adults, confusion or other mental changes may be the only sign of a UTI, and that you should call if symptoms come back soon after antibiotics [9].

A urine culture identifies the bacteria causing an infection and helps choose the right antibiotic [9]. If you get repeat infections, keeping a record of each one, and whether a culture confirmed it, helps your clinician plan prevention.

Getting help through WarriorBabe Health

WarriorBabe Health offers a low-dose estradiol vaginal cream for genitourinary symptoms of menopause. It is compounded by a licensed pharmacy under your provider's prescription. Compounded drugs are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality before they reach patients [12]. A licensed provider reviews your health history and decides whether it is appropriate for you, and not everyone will be a candidate. It is not a treatment for an active infection; if you have UTI symptoms now, see a clinician who can test and treat you [9].

Vaginal dryness and painful sex often come with the same changes; read more in vaginal dryness after menopause and our guide to vaginal estrogen cream. Not sure where to start? Take the 2-minute quiz.

Frequently asked questions

Does vaginal estrogen really prevent UTIs?

In postmenopausal women with recurrent UTIs, randomized trials have found fewer infections with vaginal estrogen than with placebo or no treatment [1, 2, 3]. The Menopause Society notes this benefit with vaginal but not oral estrogen [4]. It lowers the risk; it does not guarantee you will not get another infection.

How long does vaginal estrogen take to reduce UTIs?

There is no set timeline. The trials measured results over months: eight months in the estriol cream trial and 36 weeks in the estradiol ring trial [2, 3]. In the cream trial, healthy lactobacilli returned after one month in 61% of the women who completed estriol treatment [2]. Your clinician will check in on how you are doing over time.

Will an estrogen pill or patch prevent UTIs the same way?

The evidence is for vaginal estrogen. In the Cochrane review, estrogen pills did not reduce UTIs compared with placebo [1], and the Menopause Society notes the benefit was seen with vaginal, not oral, estrogen [4]. If you use systemic estrogen for hot flashes and still get infections, ask your clinician whether a vaginal product makes sense too.

Can I use vaginal estrogen instead of antibiotics?

Not for an active infection, which needs testing and treatment [9]. For prevention, experts now emphasize non-antibiotic options such as vaginal estrogen [6]. In head-to-head trials, though, results against preventive antibiotics were mixed [1, 5]. Your clinician can help you decide which approach, or combination, fits your situation.

Is vaginal estrogen safe if I have had breast cancer?

This needs your oncologist. The Menopause Society says low-dose vaginal estrogen for women with breast cancer should be prescribed in consultation with their oncologists [4]. A 2026 review advises caution for women with a history of hormone-sensitive cancer and individual decisions made with cancer or menopause specialists [5].

References

  1. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;(2):CD005131. pubmed.ncbi.nlm.nih.gov/18425910/
  2. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-756. pubmed.ncbi.nlm.nih.gov/8350884/
  3. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol. 1999;180(5):1072-1079. pubmed.ncbi.nlm.nih.gov/10329858/
  4. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf
  5. Ghasoub R, Mackay W, Shepherd A. Vaginal estrogen for urinary tract infection prevention: a narrative review of evidence, guidelines, and regulatory gaps. Gynecol Obstet Invest. 2026. pmc.ncbi.nlm.nih.gov/articles/PMC13456662/
  6. Siddiqui NY, Bradley MS. Updates in clinical management of recurrent urinary tract infections. Obstet Gynecol. 2025;146(5):631-644. pubmed.ncbi.nlm.nih.gov/40907025/
  7. Porcari I, Uccella S, Casprini C, et al. Vulvovaginal estrogen therapy for urinary symptoms in postmenopausal women: a review and meta-analysis. Climacteric. 2026;29(1):13-22. pubmed.ncbi.nlm.nih.gov/40569036/
  8. Munir A, Tarannum T, Saad N, Abdaal M. Effectiveness of non-antibiotic therapies in the management of recurrent urinary tract infections in women: a systematic review. Int Urogynecol J. 2026. pubmed.ncbi.nlm.nih.gov/42133003/
  9. Urinary tract infection - adults. MedlinePlus Medical Encyclopedia. National Library of Medicine. medlineplus.gov/ency/article/000521.htm
  10. Vaginal dryness. MedlinePlus Medical Encyclopedia. National Library of Medicine. medlineplus.gov/ency/article/000892.htm
  11. The Menopause Society. MenoNote: Genitourinary syndrome of menopause. Patient education. 2025. menopause.org/wp-content/uploads/for-women/MenoNote-GSM.pdf
  12. U.S. Food and Drug Administration. Human drug compounding laws. www.fda.gov/drugs/human-drug-compounding/human-drug-compounding-laws

This article is for general information. It is not medical advice and does not replace a visit with a licensed clinician who knows your history. Do not start, stop or change a medication without talking to your clinician. If you think you are having a medical emergency, call 911.

Keep reading